Edwards Lifesciences RESILIA Tissue Durability

Edwards Lifesciences announced 10-year results from its COMMENCE aortic trial, demonstrating the long-term durability and sustained performance of its proprietary RESILIA tissue. The data, presented at the 106th American Association for Thoracic Surgery Annual Meeting, showed 97.9% freedom from structural valve deterioration and 97.8% freedom from reoperation due to SVD. This advancement is significant for patients with valvular heart disease, especially younger and lower-risk individuals, as it reduces the likelihood of repeat procedures. Vikram Jaisinghani and Amit Raheja of Edwards Lifesciences highlighted the importance of these findings for lifetime patient management and the company's commitment to the MSCI Asia Pacific Index region. Jeffrey Jeswant Dillon also provided a clinical perspective on the benefits of long-term durable valve solutions.